Cytek Biosciences (CTKB) Stock: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$5.81
-0.15 (-2.52%)
▼
5d:
+1.4%
30d:
+25.76%
90d:
+26.58%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CTKB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CTKB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $5.81, which is considered extended relative to its 30-day fair value range of $4.56 to $5.54. From a valuation perspective, the stock is trading at a premium (Forward PE: 83.0) compared to its historical average (57.6). At these levels, the market is pricing in 13.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTKB is in a strong uptrend. Immediate support is located at $5.09, while resistance sits at $5.99.
Market Sentiment: CTKB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTKB is in a strong uptrend. Immediate support is located at $5.09, while resistance sits at $5.99.
Market Sentiment: CTKB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.56 -
$5.54
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.9%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($5.56)
- NEUTRAL: Trading at premium valuation - market expects 13.0% growth which is achievable
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.56 -
$5.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.09
Resistance Level
$5.99
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
83.00
Wall Street Target
$5.56
(-4.3%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
73.5%
Profit Margin
-39.0%
Valuation Premium vs History
+13.0% premium
PE vs Historical
83.0 vs 57.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.0%
(market-implied from PE analysis)
1-Year Target
$6.57
(+13%)
2-Year Target
$7.42
(+28%)
3-Year Target
$8.38
(+44%)
3-Yr Target (if PE normalizes)
(PE: 83→58)
PE COMPRESSION
$5.82
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 02, 2026 2:17 AM ET
Data refreshes hourly during market hours. Next update: 3:17 AM
Data refreshes hourly during market hours. Next update: 3:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
